INDP-D101 is the Company’s first-in-human, open label, dose escalation and expansion, multicenter Phase 1 clinical trial of its lead compound Decoy20 in patients with advanced/metastatic solid ...

The organization, which launched in August 2021, has compiled hundreds of resources on climate change for every grade and nearly every school subject.